Results 181 to 190 of about 280,326 (218)

Synergistic Therapy for Graves' Ophthalmopathy-Associated Eyelid Retraction: Steroid, 5-FU, and Botulinum Neurotoxin a Combination. [PDF]

J Clin Med
Kim Y, Lew H.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy

Thyroid, 2021
Background: We report the therapeutic use of K1-70™, a thyrotropin receptor (TSHR) antagonist monoclonal antibody, in a patient with follicular thyroid cancer (FTC), Graves' disease (GD), and Graves' ophthalmopathy (GO).
Mabel Ryder, M. Wentworth, A. Algeciras-Schimnich, J. Morris, J. Garrity, J. Sanders, Stuart Young, P. Sanders, J. Furmaniak, B. Rees Smith   +9 more
semanticscholar   +1 more source

Evaluation of Retinal Neurodegeneration and Choroidal Thickness in Patients with Inactive Gravesʼ Ophthalmopathy

Klinische Monatsblätter für Augenheilkunde, 2021
Purpose The study was conducted for the assessment of the retinal nerve fiber layer, ganglion cell layer, and subfoveal choroidal thickness changes in patients with inactive Gravesʼ ophthalmopathy (GO) using swept-source optical coherence tomography (SS ...
M. Kurt, C. Akpolat, F. Evliyaoglu, M. Yilmaz, Fikriye Ordulu   +4 more
semanticscholar   +1 more source

Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy

Experimental Eye Research, 2016
Willem A Dik, Sita Virakul
exaly   +2 more sources

Low signal intensities of MRI T1 mapping predict refractory diplopia in Graves’ ophthalmopathy

Clinical Endocrinology, 2020
In Graves’ ophthalmopathy (GO), fibrosis in extraocular muscles (EOMs) may be related to intravenous glucocorticoid (ivGC)‐resistant diplopia. Signal intensity (SI) of magnetic resonance imaging (MRI) T1 mapping can quantify properties of EOM components,
K. Matsuzawa, Shoichiro Izawa, A. Kato, Kenji Fukaya, Kazuhisa Matsumoto, Tsuyoshi Okura, D. Miyazaki, M. Kurosaki, S. Fujii, Shin‐ichi Taniguchi, Masahiko Kato, Kazuhiro Yamamoto   +11 more
semanticscholar   +1 more source

Outcome and Safety of Different Cumulative Doses and Protocols of Intravenous Methylprednisolone in Moderate to Severe and Active Graves’ Ophthalmopathy

Ophthalmologica Indonesiana, 2019
Background: Graves’ ophthalmopathy (GO), also known as Graves’ orbitopathy or thyroid eye disease, has a potential sight-threatening complications. The activity and severity are important determinants in GO and are implications for treatment. Intravenous Glucocorticoid (GC) was associated with significantly greater efficacy and
Amelya Permata Sari, M Sidik, Syntia Nusanti   +2 more
openaire   +1 more source

The expression of interleukin‐15 and interleukin‐17 in tears and orbital tissues of Graves ophthalmopathy patients

Journal of Cellular Biochemistry, 2019
The objective of this study was to study the levels of interleukin (IL)‐15 and IL‐17 in tears and orbital tissues of the patients with the Graves ophthalmopathy (GO) (active and inactive stages) and in controls.
Qun Chen
semanticscholar   +1 more source